sábado, 18 de julio de 2020

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy | Radiation Oncology | Full Text

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy | Radiation Oncology | Full Text

Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor ...
Authors:Lukas Käsmann, Chukwuka Eze, Julian Taugner, Olarn Roengvoraphoj, Maurice Dantes, Nina-Sophie Schmidt-Hegemann, Sanziana Schiopu, Claus Belka and Farkhad Manapov
Citation:Radiation Oncology 2020 15:167
Content type:Review
 
Published on: 

No hay comentarios:

Publicar un comentario